Compare CZWI & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZWI | NERV |
|---|---|---|
| Founded | 1938 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.1M | 210.1M |
| IPO Year | 2006 | 2014 |
| Metric | CZWI | NERV |
|---|---|---|
| Price | $23.36 | $4.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 115.8K | ★ 379.3K |
| Earning Date | 04-27-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 8.96 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | $13.02 | N/A |
| Revenue Next Year | $9.42 | N/A |
| P/E Ratio | $58.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.61 | $1.76 |
| 52 Week High | $24.43 | $12.46 |
| Indicator | CZWI | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 59.95 | 43.42 |
| Support Level | $20.10 | $4.30 |
| Resistance Level | $24.43 | $4.59 |
| Average True Range (ATR) | 0.74 | 0.47 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 61.20 | 21.05 |
Citizens Community Bancorp Inc is a bank holding company that offers traditional community banking services to businesses, Agricultural operators, and consumers, including one-to-four-family residential mortgages. it also offers a variety of loan products including commercial real estate loans, commercial and industrial (C&I) loans, agricultural real estate loans, agricultural operating loans, residential mortgages, home equity lines-of-credit, and consumer loans and offers deposit products through its branches, including demand deposits, various savings and money-market accounts and certificates of deposit. The company's sources of funds are deposits; amortization, prepayments, and maturities of outstanding loans; other short - term investments; and funds provided from operations.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.